Understanding the Link Between Breast Cancer and Osteoporosis

A breast cancer diagnosis marks the beginning of a long and complicated clinical journey for patients. Yet in the midst of navigating treatment, one long-term consequence often receives far less attention than it deserves: osteoporosis. For many survivors, accelerated bone loss becomes an unexpected part of that journey, as they face an almost 70% higher risk of osteoporosis compared to cancer-free individuals.

But why?

In my recent Cassling Investing In You webinar, I explored the biological connection between breast cancer and osteoporosis, the imaging tools we rely on to monitor bone health and the strategies we can use to support patients throughout treatment.

How Estrogen Supports Bone Remodeling

Bone, far from being static, is a constantly changing tissue. In fact, the human skeleton is completely renewed roughly every 10 years. This ongoing remodeling depends on a delicate balance between two cell types:

• Osteoclasts, which break down bone
• Osteoblasts, which build it back up

A healthy skeleton depends on a steady balance between these two processes.

Estrogen is one of the key regulators for bone metabolism. When estrogen levels fall, osteoclast activity increases, meaning bone is broken down faster than it can be rebuilt. Over time, this imbalance can lead to porous, weakened bones and osteoporosis.

Apart from women losing estrogen naturally, particularly during menopause, breast cancer treatments also affect estrogen levels, making women more susceptible to brittle bones.

Why Breast Cancer Treatments Increase Bone Loss Risk

About 60-80% of breast cancers are fueled by estrogen or progesterone, making them hormone receptor-positive breast cancers. While treatment is necessary for these types of cancer, the decline of estrogen levels also places patients at higher risk for accelerated bone loss.

Understanding how different forms of therapy affect the body helps explain why osteoporosis becomes a significant concern for so many patients.

Chemotherapy and Menopause-Related Changes

The ovaries are highly sensitive to chemotherapy, and the disruption of their functions can lead to temporary or early menopause. During this interruption, estrogen production decreases.

Endocrine Therapy and Aromatase Inhibitors

For patients with estrogen‑receptor‑positive breast cancers, endocrine therapy is a crucial form of treatment. Aromatase inhibitors are among the most effective medications for reducing estrogen levels, which fuel breast cancer cells, but unfortunately, they also have the greatest impact on bone health. By dramatically lowering estrogen production, these therapies increase bone resorption and heighten the risk of osteoporosis. In this way, aromatase inhibitors remain the most strongly associated with bone density loss.

Tamoxifen

Tamoxifen is another commonly used therapy, and its effects on bone vary depending on menopausal status. In premenopausal women, tamoxifen can contribute to bone loss because it blocks estrogen activity. But in postmenopausal women, it may have a protective effect due to its partial estrogen-like behavior in bone. While its effects are not considered to cause significant harm, it’s still important to think about when personalizing care.

The Role of Imaging in Early Detection and Monitoring

Imaging plays a central role in identifying and tracking bone loss in breast cancer patients. Early detection allows clinicians to intervene before fractures or severe osteoporosis develop.

DEXA Screening, The Gold Standard

Dual‑energy X‑ray absorptiometry (DEXA) is the most common and reliable method for assessing bone mineral density and diagnosing osteoporosis. It offers several advantages:

• Low radiation dose
• High accuracy and reproducibility
• Ability to track changes over time
• It is quick and painless

Many patients receive a baseline DEXA scan at the start of treatment. Follow‑up scans depend on the patient’s risk factors, treatment plan and overall health.

In cases where a DEXA screening is not accessible, QCT (Quantitative Computed Tomography) can be used to estimate bone density with a 3D assessment. Although CT involves higher radiation exposure, research suggests it may be more sensitive than DEXA in detecting osteoporosis.

Clinical Warning Signs Worth Noticing

While laboratory monitoring and hormone evaluation fall under the scope of oncology and primary care teams, imaging professionals may be the first to notice signs of compromised bone health. One of the most important red flags is unexplained fractures. These may indicate underlying osteoporosis or significant bone density loss.

Because breast cancer patients undergo multiple imaging exams, technologists and radiologists are uniquely positioned to identify early changes.

Supporting Bone Health Through Lifestyle and Prevention

Beyond imaging and medical treatment, several lifestyle strategies can help protect bone health:

• Sufficient calcium intake through diet or supplements
• Vitamin D through sunlight or supplementation
• Weight‑lifting and resistance exercise, which strengthens bone and muscle
• Balanced nutrition to support overall bone metabolism

These healthy habits are beneficial for all adults but especially important for women undergoing treatments that affect estrogen levels.

A Holistic Approach to Survivorship

The truth is, breast cancer treatment is not always a straight-forward journey, and bone health is an essential part of the survivorship conversation. By understanding how therapies influence bone remodeling, clinicians and imaging teams can help patients take proactive steps to protect their long‑term health.

Women with a family history of breast cancer can benefit from earlier and more frequent bone health evaluations than the general population. Plus, with the right combination of screening, lifestyle support and clinical awareness, patients can navigate treatment with greater confidence and maintain stronger bones well into the future.